Analysis of Immune Complexes in Multiple Sclerosis

1987 ◽  
pp. 129-137
Author(s):  
Patricia Coyle
Keyword(s):  
Multiple Sclerosis ◽  
Immune Complexes

Circulating immune complexes in patients with multiple sclerosis

1982 ◽  
Vol 55 (3) ◽  
pp. 273-283 ◽  
Author(s):  
T. Arnadottir ◽  
R. Kekomäki ◽  
G.A. Lund ◽  
M. Reunanen ◽  
A.A. Salmi
Keyword(s):  
Multiple Sclerosis ◽  
Immune Complexes ◽  
Circulating Immune Complexes

scholarly journals Antibodies to neurofilament light as potential biomarkers in multiple sclerosis

2021 ◽  
Vol 3 (2) ◽  
pp. e000192
Author(s):  
Fabiola Puentes ◽  
Pascal Benkert ◽  
Sandra Amor ◽  
Jens Kuhle ◽  
Gavin Giovannoni
Keyword(s):  
Multiple Sclerosis ◽  
Immune Complexes ◽  
Quantitative Measure ◽  
Immune Reactivity ◽  
High Avidity ◽  
Disability Score ◽  
Neurofilament Light ◽  
Prospective Longitudinal Study ◽  
Baseline Serum ◽  
Prospective Longitudinal

Background and objectiveThe concentration of neurofilament light (NfL) protein in cerebrospinal fluid (CSF) and blood is widely considered as a quantitative measure of neuro-axonal injury. Immune reactivity to NfL released into extracellular fluids induces specific autoantibody response. We investigated the levels and avidity of antibodies to NfL in patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) and their correlation with disease worsening and NfL protein concentration.MethodsWe conducted a prospective longitudinal study in 246 patients with MS (125 DMT-treated and 121 untreated at baseline). Serum levels of NfL antibodies, antibody avidity and immune complexes were determined by ELISA. NfL protein was measured using the Simoa platform. Clinical variables were tested for their association with the measured parameters in multivariate generalised estimating equation models.ResultsMultivariate analysis showed that levels of NfL antibodies were higher in progressive MS compared with clinically isolated syndrome (CIS)/relapsing remitting multiple sclerosis (RRMS) (p=0.010). Anti-NfL levels drop with increasing disability score (Expanded Disability Status Scale (EDSS)) (p=0.002), although conversely, were significantly elevated in CIS/RRMS after a recent EDSS increase (p=0.012). Patients receiving DMTs showed decreased levels of anti-NfL (p=0.008), high-avidity antibodies (p=0.017) and immune-complexes compared with untreated CIS/RRMS. Patients with MS switching to natalizumab showed lower levels of anti-NfL but higher immune complexes compared with healthy controls (p=0.0071). A weak association was observed between the levels of NfL protein and NfL antibodies.ConclusionsThese results support the potential usefulness of quantifying antibody response to NfL as potential markers of progression and treatment response in MS and need to be considered when interpreting peripheral blood NfL levels.

scholarly journals A possible case of serum sickness after ocrelizumab infusion – Commentary

2020 ◽  
Vol 27 (1) ◽  
pp. 158-159
Author(s):  
Sarmad Al-Araji ◽  
Olga Ciccarelli
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Hypersensitivity Reaction ◽  
Current Literature ◽  
Immune Complexes ◽  
Serum Sickness ◽  
The Third ◽  
Relapsing Remitting ◽  
Delayed Hypersensitivity Reaction ◽  
Relapsing Remitting Multiple Sclerosis

Serum sickness is a type III delayed hypersensitivity reaction which causes deposition of immune-complexes in the tissues. It has been reported with rituximab, and in this issue of the journal, there is a case report of a patient with relapsing remitting multiple sclerosis who developed a possible serum sickness after the third infusion of ocrelizumab. In this commentary, we discuss the current literature on serum sickness, and how to diagnose and manage it. We provide our opinion on this particular case, and encourage neurologists and patients to remain vigilant of such a possibility.

Circulating immune complexes in multiple sclerosis: Relation with disease activity

Neurology ◽  
1982 ◽  
Vol 32 (9) ◽  
pp. 1000-1000 ◽  
Author(s):  
M. K. Dasgupta ◽  
K. G. Warren ◽  
K. V. Johny ◽  
J. B. Dossetor
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Immune Complexes ◽  
Circulating Immune Complexes

Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis

2008 ◽  
Vol 14 (3) ◽  
pp. 292-299 ◽  
Author(s):  
John Parratt ◽  
Roger Tavendale ◽  
Jonathan O'Riordan ◽  
David Parratt ◽  
Robert Swingler
Keyword(s):  
Multiple Sclerosis ◽  
Immune Complexes ◽  
Odds Ratio ◽  
Chlamydia Pneumoniae ◽  
Economic Status ◽  
Cross Sectional Study ◽  
Healthy Population ◽  
Healthy Controls ◽  
Cross Sectional ◽  
Specific Serum

The significance of Chlamydia pneumoniae infection in patients with multiple sclerosis (MS) is unclear. We determined the frequency of serum C. pneumoniae-specific immune complexes in patients with MS, neurological (OND) and healthy controls in a blinded, cross-sectional study. C. pneumoniae immune complexes were detected in 24% (38/156) of MS patients, 16% (11/69) of OND and 15% (77/499) of healthy controls. The odds ratio for all MS patients was 3.95 (95% CI: 2.15 to 7.24; P < 0.0001) accounting for the covariates: sex, age, socio-economic status and area of residence. The odds ratio for recently diagnosed MS patients was 4.33 (95% CI: 1.76 to 10.64; P = 0.001). Systemic C. pneumoniae infection is more frequent in MS patients than the healthy population and occurs early in the course of the disease. Multiple Sclerosis 2007; 14: 292—299. http://msj.sagepub.com

Circulating immune complexes in serum and in cerebrospinal fluid of patients with multiple sclerosis

1988 ◽  
Vol 77 (5) ◽  
pp. 373-381 ◽  
Author(s):  
S. Procaccia ◽  
D. Lanzanova ◽  
D. Caputo ◽  
P. Ferrante ◽  
E. Papini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Immune Complexes ◽  
Circulating Immune Complexes
Sign in / Sign up

Export Citation Format

Share Document